HC Wainwright & Co. Reiterates Buy on Edgewise Therapeutics, Maintains $45 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.7%

Neg 0% Neu 90.7% Pos 0%

HC Wainwright & Co. analyst Lander Egaña Gorroño reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and maintains $45 price target.